According to the AI Finance APP, microport (00853) rose nearly 17% intraday, as of the publication, increased by 16.82%, at 7.4 Hong Kong dollars, with a turnover of 0.245 billion Hong Kong dollars.

On the news front, recently, Li Li, Director of the National Medical Products Administration, introduced at a press conference today that the vitality of China's medical and pharmaceutical innovation continues to strengthen, the pace of innovative product launches is accelerating; actively supporting the entry of innovative drugs and devices into hospitals and medical insurance; promoting global drug research and development, simultaneous application, simultaneous evaluation, and simultaneous market approval in China. Deputy Director of the National Medical Products Administration, Lei Ping, stated that the National Medical Products Administration is fully promoting the R&D innovation of medical instruments, and pushing for research results to be quickly transformed into innovative products.

gtja previously released a research report pointing out that the company's innovative business continued to maintain high-speed growth during the first half of 2024, with revenue from major arterial and peripheral intervention business at 0.11 billion U.S. dollars (+26.3%), revenue from neural intervention business at 0.057 billion U.S. dollars (+36.5%), revenue from structural heart business at 0.031 billion U.S. dollars (+26.7%), and revenue from surgical robot business at 0.01 billion U.S. dollars (+117%). The bank believes that in the first half of 2024, the company adjusted its R&D focus, while reducing R&D costs and improving R&D efficiency, ensuring steady progress in the research and development pipeline of core products, and expects the competitiveness on the R&D side to be maintained.